Acute Sinusitis Companies | Market Research Future

Top Industry Leaders in the Acute Sinusitis Market

Acute Sinusitis Key Companies *Disclaimer: List of key companies in no particular orderLatest acute sinusitis Companies Update

May 2023: Zocdoc, the premier healthcare marketplace, announced that it is expanding to include Urgent treatment, making it easier for patients to identify and book in-person or virtual treatment across more than two hundred specialities and more than twelve thousand insurance types. More than two hundred urgent care centers in 22 states are now available for online appointment booking through Zocdoc. In fact, Urgent Care is one of the fastest-growing Zocdoc care categories, both for patients and providers. In 2023, the number of new Zocdoc urgent care facilities increased by nearly 40% month over month, and bookings for urgent care appointments increased by an average of 80% month over month. Sinusitis is one type of infection that Zocdoc patients seek treatment for at urgent care clinics.

May 2023: The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental new drug application (sNDA) submitted by the pharmaceutical company Optinose for approval of XHANCE as a treatment for chronic rhinosinusitis. The XHANCE (fluticasone propionate) nasal spray combines the most popular nasal anti-inflammatory medicine with the cutting-edge Exhalation Delivery System (EDS) to create a revolutionary drug-device combo solution. The EDS was developed to provide a novel method of medication delivery, namely into the sinuses and sinonasal drainage systems, which can be difficult to reach. The ReOpen Program's sNDA filing has been given a December 16, 2023 Prescription Drug User Fee Act (PDUFA) target goal date, which is based on results from two Phase 3 clinical studies in patients with chronic sinusitis.List of acute sinusitis Key companies in the market